Misop Han

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12205226/publications.pdf

Version: 2024-02-01

		44069	27406
128	11,514	48	106
papers	citations	h-index	g-index
129	129	129	9671
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. European Urology, 2016, 69, 428-435.	1.9	1,039
2	LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 555-565.	1.8	939
3	CANCER PROGRESSION AND SURVIVAL RATES FOLLOWING ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY IN 3,478 CONSECUTIVE PATIENTS: LONG-TERM RESULTS. Journal of Urology, 2004, 172, 910-914.	0.4	781
4	Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer. Journal of Urology, 2003, 169, 517-523.	0.4	691
5	Prostate Cancer–Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy. JAMA - Journal of the American Medical Association, 2008, 299, 2760.	7.4	586
6	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. Journal of Urology, 2011, 185, 869-875.	0.4	574
7	POTENCY, CONTINENCE AND COMPLICATIONS IN 3,477 CONSECUTIVE RADICAL RETROPUBIC PROSTATECTOMIES. Journal of Urology, 2004, 172, 2227-2231.	0.4	506
8	Prostate Specific Antigen Best Practice Statement: 2009 Update. Journal of Urology, 2009, 182, 2232-2241.	0.4	362
9	An updated prostate cancer staging nomogram (<scp>P</scp> artin tables) based on cases from 2006 to 2011. BJU International, 2013, 111, 22-29.	2.5	323
10	PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 6563-6573.	7.0	309
11	Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. Journal of Urology, 2003, 169, 517-23.	0.4	271
12	ERA SPECIFIC BIOCHEMICAL RECURRENCE-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2001, 166, 416-419.	0.4	266
13	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology, 2017, 71, 740-747.	1.9	256
14	African American Men With Very Low–Risk Prostate Cancer Exhibit Adverse Oncologic Outcomes After Radical Prostatectomy: Should Active Surveillance Still Be an Option for Them?. Journal of Clinical Oncology, 2013, 31, 2991-2997.	1.6	220
15	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 157-165.	1.9	206
16	¹⁸ F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 1003-1010.	5.0	180
17	PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathology, 2015, 28, 128-137.	5.5	136
18	An Evaluation of the Decreasing Incidence of Positive Surgical Margins in a Large Retropubic Prostatectomy Series. Journal of Urology, 2004, 171, 23-26.	0.4	133

#	Article	IF	Citations
19	Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology, 2003, 62, 86-91.	1.0	117
20	Contemporary Evaluation of the D'Amico Risk Classification of Prostate Cancer. Urology, 2007, 70, 931-935.	1.0	111
21	Impact of surgical technique (open vs laparoscopic vs roboticâ€assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. BJU International, 2011, 107, 1956-1962.	2.5	97
22	Contemporary Evaluation of the National Comprehensive Cancer Network Prostate Cancer Risk Classification System. Urology, 2012, 80, 1075-1079.	1.0	91
23	Prediction of pathological stage based on clinical stage, serum prostateâ€specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. BJU International, 2017, 119, 676-683.	2.5	86
24	Pathological Characteristics of Prostate Cancer Detected Through Prostate Specific Antigen Based Screening. Journal of Urology, 2006, 175, 902-906.	0.4	78
25	Cigarette Smoking and Prostate Cancer Recurrence After Prostatectomy. Journal of the National Cancer Institute, 2011, 103, 835-838.	6.3	78
26	Prediction of Mortality After Radical Prostatectomy by Charlson Comorbidity Index. Urology, 2010, 76, 553-557.	1.0	77
27	Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology, 2001, 57, 1033-1037.	1.0	76
28	Weight Gain Is Associated with an Increased Risk of Prostate Cancer Recurrence after Prostatectomy in the PSA Era. Cancer Prevention Research, 2011, 4, 544-551.	1.5	75
29	Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. Urology, 2018, 115, 39-44.	1.0	75
30	Prostate Specific Antigen Best Practice Statement: 2009 Update. Journal of Urology, 2013, 189, S2-S11.	0.4	74
31	Natural History of Pathologically Organ-Confined (pT2), Gleason Score 6 or Less, Prostate Cancer After Radical Prostatectomy. Urology, 2008, 72, 172-176.	1.0	73
32	Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?. Urology, 2001, 58, 746-751.	1.0	71
33	SALVAGE RADIATION THERAPY FOR PROSTATE SPECIFIC ANTIGEN PROGRESSION FOLLOWING RADICAL PROSTATECTOMY: 10-YEAR OUTCOME ESTIMATES. Journal of Urology, 2005, 174, 1282-1286.	0.4	70
34	A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy. Journal of Urology, 2011, 185, 1691-1697.	0.4	70
35	A Critical Analysis of the Interpretation of Biochemical Failure in Surgically Treated Patients Using the American Society for Therapeutic Radiation and Oncology Criteria. Journal of Urology, 2002, 168, 1419-1422.	0.4	69
36	Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. European Urology, 2017, 71, 697-700.	1.9	65

#	Article	IF	CITATIONS
37	Tandem-robot Assisted Laparoscopic Radical Prostatectomy to Improve the Neurovascular Bundle Visualization: A Feasibility Study. Urology, 2011, 77, 502-506.	1.0	64
38	Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. Cancer, 2001, 91, 1661-1666.	4.1	62
39	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	5.5	57
40	ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE. Journal of Urology, 2000, 164, 89-92.	0.4	56
41	Racial Disparities in Oncologic Outcomes After Radical Prostatectomy: Long-term Follow-up. Urology, 2014, 84, 1434-1441.	1.0	56
42	MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clinical Cancer Research, 2018, 24, 3668-3680.	7.0	56
43	Long-term Survival After Radical Prostatectomy for Men With High Gleason Sum in Pathologic Specimen. Urology, 2010, 76, 715-721.	1.0	55
44	Geometric Evaluation of Systematic Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology, 2012, 188, 2404-2409.	0.4	54
45	Expanded Criteria to Identify Men Eligible for Active Surveillance of Low Risk Prostate Cancer at Johns Hopkins: A Preliminary Analysis. Journal of Urology, 2013, 190, 2033-2038.	0.4	52
46	Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate, 2013, 73, 1673-1680.	2.3	51
47	Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology, 2005, 66, 156-160.	1.0	50
48	Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA Era. Urology, 2007, 70, 950-955.	1.0	50
49	Impact of Body Mass Index on Biochemical Recurrence Rates After Radical Prostatectomy: An Analysis Utilizing Propensity Score Matching. Urology, 2008, 72, 1246-1251.	1.0	48
50	A Prospective Cohort Study of Postdischarge Opioid Practices After Radical Prostatectomy: The ORIOLES Initiative. European Urology, 2019, 75, 215-218.	1.9	48
51	Obesity and Long-Term Survival after Radical Prostatectomy. Journal of Urology, 2014, 192, 1100-1104.	0.4	47
52	The Relationship Between the Extent of Extraprostatic Extension and Survival Following Radical Prostatectomy. European Urology, 2015, 67, 342-346.	1.9	47
53	Viewpoint: Expanding Prostate Cancer Screening. Annals of Internal Medicine, 2006, 144, 441.	3.9	44
54	New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8–10 Prostate Cancer. European Urology, 2017, 71, 907-912.	1.9	44

#	Article	IF	CITATIONS
55	Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. Journal of Urology, 2016, 195, 337-342.	0.4	43
56	Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance. Urology, 2013, 81, 831-836.	1.0	40
57	Ultrasound Probe and Needle-Guide Calibration for Robotic Ultrasound Scanning and Needle Targeting. IEEE Transactions on Biomedical Engineering, 2013, 60, 1728-1734.	4.2	40
58	Contemporaneous comparison of open vs minimallyâ€invasive radical prostatectomy for highâ€risk prostate cancer. BJU International, 2013, 112, 751-757.	2.5	40
59	Preoperative characteristics of highâ€Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU International, 2012, 110, 1122-1128.	2.5	39
60	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. Journal of Urology, 2016, 196, 1436-1444.	0.4	38
61	More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology, 2006, 67, 343-348.	1.0	37
62	Robotic Transrectal Ultrasound Guided Prostate Biopsy. IEEE Transactions on Biomedical Engineering, 2019, 66, 2527-2537.	4.2	37
63	Outcomes of very highâ€risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer, 2019, 125, 391-397.	4.1	37
64	Progression after radical prostatectomy for men in their thirties compared to older men. BJU International, 2008, 101, 1503-1506.	2.5	36
65	Prediction of patientâ€specific risk and percentile cohort risk of pathological stage outcome using continuous prostateâ€specific antigen measurement, clinical stage and biopsy Gleason score. BJU International, 2011, 107, 1562-1569.	2.5	36
66	Variability in Medicare Utilization and Payment Among Urologists. Urology, 2015, 85, 1045-1051.	1.0	36
67	Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediateâ€risk to veryâ€highâ€risk clinically localised prostate cancer. BJU International, 2019, 124, 268-274.	2.5	36
68	A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia. Nutrition and Cancer, 2015, 67, 1104-1112.	2.0	35
69	Black Race Does Not Independently Predict Adverse Outcome Following Radical Retropubic Prostatectomy at a Tertiary Referral Center. Journal of Urology, 2006, 176, 515-519.	0.4	34
70	An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers. Cancer Research, 2016, 76, 1055-1065.	0.9	31
71	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. Journal of Urology, 2001, 165, 864-866.	0.4	30
72	Prostate Specific Antigen Versus Prostate Specific Antigen Density as a Prognosticator of Pathological Characteristics and Biochemical Recurrence Following Radical Prostatectomy. Journal of Urology, 2008, 179, 1780-1784.	0.4	30

#	Article	IF	CITATIONS
73	Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surgical Oncology, 2009, 18, 268-274.	1.6	29
74	Allogeneic versus autologous blood transfusion and survival after radical prostatectomy (CME). Transfusion, 2014, 54, 2168-2174.	1.6	29
75	Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU International, 2010, 106, 791-795.	2.5	28
76	The effect of limited (tertiary) Gleason pattern 5 on the new prostate cancer grade groups. Human Pathology, 2017, 63, 27-32.	2.0	28
77	Robotic ultrasound and needle guidance for prostate cancer management. Current Opinion in Urology, 2014, 24, 75-80.	1.8	27
78	Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance. Journal of Urology, 2018, 199, 1482-1487.	0.4	27
79	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer, 2019, 17, 470-475.e1.	1.9	26
80	Aspirin and Non-Aspirin NSAID Use and Prostate Cancer Incidence, Mortality, and Case Fatality in the Atherosclerosis Risk in Communities Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 563-569.	2.5	26
81	Effect of a prospective opioid reduction intervention on opioid prescribing and use after radical prostatectomy: results of the Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery (ORIOLES) Initiative. BJU International, 2020, 125, 426-432.	2.5	26
82	Endocavity Ultrasound Probe Manipulators. IEEE/ASME Transactions on Mechatronics, 2013, 18, 914-921.	5.8	24
83	Identification of men with the highest risk of early disease recurrence after radical prostatectomy. Prostate, 2014, 74, 628-636.	2.3	24
84	Causes of Death After Radical Prostatectomy at a Large Tertiary Center. Journal of Urology, 2012, 188, 798-802.	0.4	23
85	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 496-504.	1.9	23
86	Evolution of the clinical presentation of men undergoing radical prostatectomy for highâ€risk prostate cancer. BJU International, 2012, 109, 988-993.	2.5	22
87	Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. European Urology, 2020, 78, 360-368.	1.9	22
88	Radical Prostatectomy Outcome in Men 65 Years Old or Older With Low Risk Prostate Cancer. Journal of Urology, 2012, 187, 1620-1625.	0.4	20
89	Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature. BJU International, 2014, 114, E120-E129.	2.5	20
90	Comparison of Perioperative and Pathologic Outcomes Between Single-port and Standard Robot-assisted Radical Prostatectomy: An Analysis of a High-volume Center and the Pooled World Experience. Urology, 2021, 147, 223-229.	1.0	20

#	Article	IF	CITATIONS
91	Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Urology, 2004, 64, 723-728.	1.0	19
92	Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy. Journal of Urology, 2009, 182, 491-498.	0.4	18
93	Practice Patterns and Individual Variability of Surgeons Performing Radical Prostatectomy at a High Volume Academic Center. Journal of Urology, 2015, 193, 812-819.	0.4	14
94	Nomograms for clinically localized prostate cancer. Part I: Radical prostatectomy. Urologic Oncology, 2002, 20, 123-130.	1.5	14
95	The impact of preoperative erectile dysfunction on survival after radical prostatectomy. BJU International, 2010, 106, 1612-1617.	2.5	13
96	Adenocarcinoma of the Prostate with Gleason Score 9-10 on Core Biopsy: Correlation with Findings at Radical Prostatectomy and Prognosis. Journal of Urology, 2013, 190, 2068-2073.	0.4	13
97	Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series. BJU International, 2017, 119, 444-448.	2.5	13
98	PTEN status assessment in the Johns Hopkins active surveillance cohort. Prostate Cancer and Prostatic Diseases, 2019, 22, 176-181.	3.9	13
99	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. PLoS ONE, 2016, 11, e0146189.	2.5	13
100	Instrument Life for Robot-assisted Laparoscopic Radical Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified?. Urology, 2015, 86, 942-946.	1.0	10
101	The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. Journal of Urology, 2017, 197, 1060-1067.	0.4	10
102	Call Schedule and Sleep Patterns of Urology Residents Following the 2011 ACGME Reforms. Urology Practice, 2016, 3, 147-152.	0.5	9
103	Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy. Journal of Urology, 2019, 201, 937-942.	0.4	7
104	The role of free prostate-specific antigen in prostate cancer detection. Current Urology Reports, 2000, 1, 78-82.	2.2	6
105	Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. World Journal of Urology, 2011, 29, 11-14.	2.2	6
106	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Medical Oncology, 2022, 39, 63.	2.5	6
107	The prostate tissueâ€based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. Journal of Pathology: Clinical Research, 2022, 8, 481-491.	3.0	6
108	Imaging guidance in minimally invasive prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 343-346.	1.6	5

#	Article	IF	CITATIONS
109	Risk Factors for Intraprostatic Incision into Malignant Glands at Radical Prostatectomy. European Urology, 2015, 68, 311-316.	1.9	5
110	Geometric systematic prostate biopsy. Minimally Invasive Therapy and Allied Technologies, 2017, 26, 78-85.	1.2	5
111	Non-steroidal anti-androgens in prostate cancer - current treatment practice. Expert Opinion on Pharmacotherapy, 2000, 1, 443-449.	1.8	4
112	Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 589-594.	1.6	4
113	Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: Effect on hospitalization. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e7-158.e12.	1.6	4
114	Patient and in-hospital predictors of post-discharge opioid utilization: Individualizing prescribing after radical prostatectomy based on the ORIOLES initiative. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 104.e9-104.e15.	1.6	4
115	Optimizing the Management of High-Risk, Localized Prostate Cancer. Korean Journal of Urology, 2012, 53, 815.	1.2	3
116	Rare Renal Incidentaloma in Pregnancy: An Unusual Primitive Neuroectodermal Tumor Presentation. Urology Case Reports, 2015, 3, 12-14.	0.3	3
117	Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer. Cancer Prevention Research, 2021, 14, 463-470.	1.5	3
118	KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression. Prostate Cancer and Prostatic Diseases, 2022, , .	3.9	3
119	Robot for ultrasound-guided prostate imaging and intervention. , 2011, , .		2
120	Definitive Therapy for Localized Prostate Cancer. , 2012, , 2771-2788.e6.		2
121	Urologist Scores in the Era of the Merit-Based Incentive Payment System (MIPS). Urology Practice, 2022, 9, 119-125.	0.5	2
122	Pelvic Lymph Node Dissection During Laparoscopic/Robotic Prostatectomy. Journal of Urology, 2011, 185, 1667-1667.	0.4	1
123	Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8–10 Prostate Cancer. Eur Urol 2017:71:907–12. European Urology. 2017. 72. e11-e12.	1.9	1
124	Reducing preoperative blood orders and costs for radical prostatectomy. Journal of Comparative Effectiveness Research, 2020, 9, 219-226.	1.4	1
125	Brachytherapy for prostate cancer: feasible but oncological equivalence unproven. BJU International, 2015, 116, 89-91.	2.5	О
126	Reply. Urology, 2015, 85, 1051.	1.0	0

#	Article	IF	CITATIONS
127	Open Radical Retropubic Prostatectomy: Technique and Outcomes. , 2010, , 105-119.		O
128	Early initiation of salvage radiotherapy is associated with improved metastasis-free survival in patients with relapsed prostate cancer following prostatectomy. Journal of Clinical Oncology, 2022, 40, 262-262.	1.6	0